These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37259686)

  • 1. Parallel testing of liquid biopsy (ctDNA) and tissue biopsy samples reveals a higher frequency of EZH2 mutations in follicular lymphoma.
    Nagy Á; Bátai B; Kiss L; Gróf S; Király PA; Jóna Á; Demeter J; Sánta H; Bátai Á; Pettendi P; Szendrei T; Plander M; Körösmezey G; Alizadeh H; Kajtár B; Méhes G; Krenács L; Timár B; Csomor J; Tóth E; Schneider T; Mikala G; Matolcsy A; Alpár D; Masszi A; Bödör C
    J Intern Med; 2023 Sep; 294(3):295-313. PubMed ID: 37259686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma.
    Julia E; Salles G
    Future Oncol; 2021 Jun; 17(17):2127-2140. PubMed ID: 33709777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative Analysis and Monitoring of EZH2 Mutations Using Liquid Biopsy in Follicular Lymphoma.
    Nagy Á; Bátai B; Balogh A; Illés S; Mikala G; Nagy N; Kiss L; Kotmayer L; Matolcsy A; Alpár D; Masszi T; Masszi A; Bödör C
    Genes (Basel); 2020 Jul; 11(7):. PubMed ID: 32668764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
    Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
    Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.
    Martínez-Laperche C; Sanz-Villanueva L; Díaz Crespo FJ; Muñiz P; Martín Rojas R; Carbonell D; Chicano M; Suárez-González J; Menárguez J; Kwon M; Diez Martín JL; Buño I; Bastos Oreiro M
    BMC Cancer; 2022 Sep; 22(1):982. PubMed ID: 36104682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
    Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
    Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients.
    Shyu JY; Schlag PA; Karwowska SM; Manohar CF; Truong HM; Longshore JW; Zhang G
    PLoS One; 2023; 18(12):e0292251. PubMed ID: 38096164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tazemetostat: a treatment option for relapsed/refractory follicular lymphoma.
    Mondello P; Ansell SM
    Expert Opin Pharmacother; 2022 Feb; 23(3):295-301. PubMed ID: 34904909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.
    Alcaide M; Yu S; Bushell K; Fornika D; Nielsen JS; Nelson BH; Mann KK; Assouline S; Johnson NA; Morin RD
    Clin Chem; 2016 Sep; 62(9):1238-47. PubMed ID: 27440511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [INHIBITORY EZH2 NOWĄ OPCJĄ TERAPEUTYCZNĄ W LECZENIU NAWROTOWEGO LUB OPORNEGO CHŁONIAKA GRUDKOWEGO EZH2 INHIBITORS AS A NEW THERAPEUTIC OPTION FOR THE TREATMENT OF RELAPSED OR RECURRENT FOLLICULAR LYMPHOMA].
    Kwiatek M; Pruchniewski Ł; Kwiatek J; Kaźmierczak M; Lewandowski K
    Wiad Lek; 2018; 71(5):1095-1098. PubMed ID: 30176648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 alterations in follicular lymphoma: biological and clinical correlations.
    Huet S; Xerri L; Tesson B; Mareschal S; Taix S; Mescam-Mancini L; Sohier E; Carrère M; Lazarovici J; Casasnovas O; Tonon L; Boyault S; Hayette S; Haioun C; Fabiani B; Viari A; Jardin F; Salles G
    Blood Cancer J; 2017 Apr; 7(4):e555. PubMed ID: 28430172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 mutations in follicular lymphoma from different ethnic groups and associated gene expression alterations.
    Guo S; Chan JK; Iqbal J; McKeithan T; Fu K; Meng B; Pan Y; Cheuk W; Luo D; Wang R; Zhang W; Greiner TC; Chan WC
    Clin Cancer Res; 2014 Jun; 20(12):3078-86. PubMed ID: 24634383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetics of Indolent Lymphoma and How It Drives Novel Therapeutic Approaches-Focus on EZH2-Targeted Drugs.
    Longley J; Johnson PWM
    Curr Oncol Rep; 2021 May; 23(7):76. PubMed ID: 33937922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2 mutations are frequent and represent an early event in follicular lymphoma.
    Bödör C; Grossmann V; Popov N; Okosun J; O'Riain C; Tan K; Marzec J; Araf S; Wang J; Lee AM; Clear A; Montoto S; Matthews J; Iqbal S; Rajnai H; Rosenwald A; Ott G; Campo E; Rimsza LM; Smeland EB; Chan WC; Braziel RM; Staudt LM; Wright G; Lister TA; Elemento O; Hills R; Gribben JG; Chelala C; Matolcsy A; Kohlmann A; Haferlach T; Gascoyne RD; Fitzgibbon J
    Blood; 2013 Oct; 122(18):3165-8. PubMed ID: 24052547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
    Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
    Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein.
    Gángó A; Bátai B; Varga M; Kapczár D; Papp G; Marschalkó M; Kuroli E; Schneider T; Csomor J; Matolcsy A; Bödör C; Szepesi Á
    Virchows Arch; 2018 Oct; 473(4):453-462. PubMed ID: 29858685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging EZH2 Inhibitors and Their Application in Lymphoma.
    Lue JK; Amengual JE
    Curr Hematol Malig Rep; 2018 Oct; 13(5):369-382. PubMed ID: 30112706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.